The largest medtech deal of 2026 closes a turbulent chapter — and opens a more consequential one.
What Happened
This morning, Masimo Corporation (NASDAQ: MASI) announced a definitive all-cash agreement to be acquired by Danaher Corporation (NYSE: DHR) at $180 per share, representing a $9.9 billion enterprise value including assumed debt. The price carries a 38–40% premium over Masimo's February 13 close of ~$130. Both boards approved the deal unanimously. Close is targeted for the second half of 2026, pending regulatory review and Masimo shareholder approval. Danaher will fund the transaction with cash on hand and debt.
Masimo — founded in 1989 as a garage startup by engineer Joe Kiani — pioneered Signal Extraction Technology pulse oximetry, a non-invasive method for measuring blood oxygen that cut false alarms by 95% and became the standard at all 10 top U.S. hospitals per the 2025 Newsweek ranking. Its technology monitors over 200 million patients annually. The company also developed the Opioid Halo overdose monitoring system, the Doctella home-care platform, and holds partnerships with Philips, GE Healthcare, Cleveland Clinic, and Google. Full-year 2025 revenue came in at ~$1.52 billion, up 9%.
Masimo will sit as a standalone unit inside Danaher's Diagnostics segment, alongside Beckman Coulter, Cepheid, and Radiometer. Danaher CEO Rainer Blair called Masimo's brand and technology a significant enhancement to its diagnostics business. Danaher projects Masimo will generate over $530 million in 2027 EBITDA, with more than $125 million in annual cost synergies and $50 million in revenue synergies by year five — driving EPS accretion from $0.10–0.20 in year one to ~$0.50 by year five.
The Chaos That Made This Deal Inevitable
This acquisition is the direct product of four years of corporate wreckage. In 2022, Masimo spent $1 billion acquiring Sound United, a consumer audio company — a move that activist investor Politan Capital Management, holding a 9% stake, deemed an inexcusable distraction from acute care medtech. Politan waged a prolonged proxy war, attacking Masimo's governance, strategic drift, and underperformance. The campaign succeeded: founder and longtime CEO Joe Kiani was ousted in September 2024. Michelle Brennan served as interim CEO before becoming board chairman. Katie Szyman, formerly worldwide president of Advanced Patient Monitoring at Becton Dickinson, was appointed permanent CEO on February 12, 2025 — barely twelve months before today's announcement.
The board, per chairman Michelle Brennan, "meticulously assessed a variety of options over recent months, including pursuing an independent strategy, and engaged with several potential partners" before concluding Danaher represented the most value-enhancing path. Translation: this is an activist endgame, and Politan wins.
The Market Read and the Arb Spread
The tape confirmed the narrative's complexity. MASI surged ~35% to ~$174.50; DHR fell ~3.7% to ~$204.65. The $5.50 gross spread between MASI's current price and the $180 cash consideration is not a panic spread — it is a measured time and risk discount consistent with a 2H 2026 close, standard regulatory process, and zero bidding war priced in. The market says: deal closes, probably.
The Real Investment Question: What Is Danaher Actually Buying?
Here is the sharpest framing of this deal: Danaher is not buying a pulse-ox widget. It is buying installed base, hospital workflow permission, and clinical credibility that took Masimo three decades to accumulate and cannot be replicated quickly by any competitor. That embedded footprint — sticky contracts, IDN relationships, bedside workflow integration — is the durable asset. The sensors are the evidence; the relationships are the moat.
The most underappreciated synergy is not cross-selling a monitor with a lab instrument. It is hospital procurement bundling (integrated delivery networks strongly prefer fewer vendors), service and software attach (where the real margin and retention live), and global channel acceleration through Danaher's international distribution machine, which is formidable.
The valuation — 18x 2027 EBITDA pre-synergies, ~15x post — looks expensive only if you believe Masimo's margins are structurally capped. If the Danaher Business System , which successfully overhauled Cepheid and Abcam post-acquisition, can attack procurement, rationalize SKUs, and impose SG&A discipline, 18x on 2027 compresses to 12–14x on 2028–2029 reality. The swing factor is top-line acceleration, not cost cuts.
One legitimate risk: Masimo's ongoing patent dispute with Apple over pulse oximetry in consumer wearables is either a hidden licensing asset or a management bandwidth drain. Danaher is historically skilled at isolating legal distractions inside operating units — but the uncertainty warrants a higher discount rate than the deal deck suggests.
The Verdict for Investors
For MASI holders: the market is saying take the money, and that is the rational call. After activism, founder removal, strategic detours, and a revolving CEO door, a clean 40% all-cash premium offers certainty no standalone re-rating story could credibly match in the near term.
For DHR holders: the near-term pressure is real — markets hate big M&A combined with debt and integration risk. But Danaher is one of the rare acquirers whose post-close operational track record actually justifies underwriting the premium. The risk is not catastrophic failure; it is that this becomes a "good business bought at a great-business price" — value-preserving, but upside-capping. On a three-to-five year horizon, constructive is the right posture. Watch the February 26 Masimo earnings release, HSR antitrust milestones, and early signs of "Danaherization" — procurement savings, service attach growth, and international penetration — as the leading indicators of whether this deal earns its price.
not investment advice